Spectrum of BRCA1/2 point mutations and genomic rearrangements in high-risk breast/ovarian cancer Chilean families
The distribution of BRCA1/2 germline mutations in breast/ovarian cancer (BC/OC) families varies among different populations. In the Chilean population, there are only two reports of mutation analysis of BRCA1/2 , and these included a low number of BC and/or OC patients. Moreover, the prevalence of B...
Gespeichert in:
Veröffentlicht in: | Breast cancer research and treatment 2011-04, Vol.126 (3), p.705-716 |
---|---|
Hauptverfasser: | , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 716 |
---|---|
container_issue | 3 |
container_start_page | 705 |
container_title | Breast cancer research and treatment |
container_volume | 126 |
creator | Gonzalez-Hormazabal, Patricio Gutierrez-Enriquez, Sara Gaete, Daniel Reyes, Jose M. Peralta, Octavio Waugh, Enrique Gomez, Fernando Margarit, Sonia Bravo, Teresa Blanco, Rafael Diez, Orland Jara, Lilian |
description | The distribution of
BRCA1/2
germline mutations in breast/ovarian cancer (BC/OC) families varies among different populations. In the Chilean population, there are only two reports of mutation analysis of
BRCA1/2
, and these included a low number of BC and/or OC patients. Moreover, the prevalence of
BRCA1/2
genomic rearrangements in Chilean and in other South American populations is unknown. In this article, we present the mutation-detection data corresponding to a set of 326 high-risk families analyzed by conformation-sensitive gel electrophoresis and heteroduplex analysis. To determine the contribution of
BRCA1/2
LGRs in Chilean BC patients, we analyzed 56 high-risk subjects with no pathogenic
BRCA1/2
point mutations. Germline
BRCA1
/
2
point mutations were found in 23 (7.1%) of the 326 Chilean families. Families which had at least three BC and/or OC cases showed the highest frequency of mutations (15.9%). We identified 14 point pathogenic mutations. Three recurrent mutations in
BRCA1
(c.187_188delAG, c.2605_2606delTT, and c.3450_3453delCAAG) and three in
BRCA2
(c.4969_4970insTG, c.5374_5377delTATG, and c.6503_6504delTT) contributed to 63.6 and 66.7% of all the deleterious mutations of each gene, which may reflect the presence of region-specific founder effects. Taken together
BRCA1/2
recurrent point mutations account for 65.2% (15/23) of the
BRCA1/2
(+) families. No large deletions or duplications involving
BRCA1
/
2
were identified in a subgroup of 56 index cases negative for
BRCA1/2
point mutations. Our study, which is the largest conducted to date in a South American population, provides a comprehensive analysis on the type and distribution of
BRCA1/2
mutations and allelic variants. |
doi_str_mv | 10.1007/s10549-010-1170-y |
format | Article |
fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_857482891</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A355939429</galeid><sourcerecordid>A355939429</sourcerecordid><originalsourceid>FETCH-LOGICAL-c574t-c76eb9c2a2c2431537eea4300793376ee533f65acf0ec2a7f9bd3de763bd5cfe3</originalsourceid><addsrcrecordid>eNp9ktuO0zAQhiMEYruFB-AGWaAFbrL1IY7jy1JxklZC4nAduc649ZLYxU6Q-vZMaWFZBMgX1mi-mdE_8xfFI0YvGaVqkRmVlS4poyVjipb7O8WMSSVKxZm6W8woq1VZN7Q-K85zvqaUakX1_eKM00bqWqlZkT7uwI5pGkh05OWH1ZItONlFH0YyTKMZfQyZmNCRDYQ4eEsSmJRM2MAAYczEB7L1m22ZfP5C1pjM4yJ-M8mbQKwJFhJZbX0PGDoz-N5DflDcc6bP8PD0z4vPr199Wr0tr96_ebdaXpVWqmosraphrS033PJKMCkUgKkE6tZCYA6kEK6WxjoKSCmn153oQNVi3UnrQMyL58e-uxS_TpDHdvDZQt-bAHHKbYNjGt5ohuSL_5KMMqWbmlca0Sd_oNdxSgF1YL-mUkxSidDTI7QxPbQ-uDgmYw8926WQUgtd8UOry79Q-DrARccADvd2u-DZbwVbMP24zbGffhzpNsiOoE0x5wSu3SU_mLRHJe3BOe3ROS09xOicdo81j0_CpvUA3a-Kn1ZB4OIEmGxN79AE1ucbTuiGUzzNvOBHLmMKfZJuNvTv6d8BAkTZcQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>858471505</pqid></control><display><type>article</type><title>Spectrum of BRCA1/2 point mutations and genomic rearrangements in high-risk breast/ovarian cancer Chilean families</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Gonzalez-Hormazabal, Patricio ; Gutierrez-Enriquez, Sara ; Gaete, Daniel ; Reyes, Jose M. ; Peralta, Octavio ; Waugh, Enrique ; Gomez, Fernando ; Margarit, Sonia ; Bravo, Teresa ; Blanco, Rafael ; Diez, Orland ; Jara, Lilian</creator><creatorcontrib>Gonzalez-Hormazabal, Patricio ; Gutierrez-Enriquez, Sara ; Gaete, Daniel ; Reyes, Jose M. ; Peralta, Octavio ; Waugh, Enrique ; Gomez, Fernando ; Margarit, Sonia ; Bravo, Teresa ; Blanco, Rafael ; Diez, Orland ; Jara, Lilian</creatorcontrib><description>The distribution of
BRCA1/2
germline mutations in breast/ovarian cancer (BC/OC) families varies among different populations. In the Chilean population, there are only two reports of mutation analysis of
BRCA1/2
, and these included a low number of BC and/or OC patients. Moreover, the prevalence of
BRCA1/2
genomic rearrangements in Chilean and in other South American populations is unknown. In this article, we present the mutation-detection data corresponding to a set of 326 high-risk families analyzed by conformation-sensitive gel electrophoresis and heteroduplex analysis. To determine the contribution of
BRCA1/2
LGRs in Chilean BC patients, we analyzed 56 high-risk subjects with no pathogenic
BRCA1/2
point mutations. Germline
BRCA1
/
2
point mutations were found in 23 (7.1%) of the 326 Chilean families. Families which had at least three BC and/or OC cases showed the highest frequency of mutations (15.9%). We identified 14 point pathogenic mutations. Three recurrent mutations in
BRCA1
(c.187_188delAG, c.2605_2606delTT, and c.3450_3453delCAAG) and three in
BRCA2
(c.4969_4970insTG, c.5374_5377delTATG, and c.6503_6504delTT) contributed to 63.6 and 66.7% of all the deleterious mutations of each gene, which may reflect the presence of region-specific founder effects. Taken together
BRCA1/2
recurrent point mutations account for 65.2% (15/23) of the
BRCA1/2
(+) families. No large deletions or duplications involving
BRCA1
/
2
were identified in a subgroup of 56 index cases negative for
BRCA1/2
point mutations. Our study, which is the largest conducted to date in a South American population, provides a comprehensive analysis on the type and distribution of
BRCA1/2
mutations and allelic variants.</description><identifier>ISSN: 0167-6806</identifier><identifier>EISSN: 1573-7217</identifier><identifier>DOI: 10.1007/s10549-010-1170-y</identifier><identifier>PMID: 20859677</identifier><identifier>CODEN: BCTRD6</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Adult ; Biological and medical sciences ; BRCA1 protein ; BRCA2 protein ; Breast cancer ; Breast Neoplasms - genetics ; Breast Neoplasms, Male - genetics ; Cancer ; Cancer research ; Chile ; Data processing ; Epidemiology ; Exons ; Family Health ; Female ; Female genital diseases ; Founder Effect ; Gel electrophoresis ; Gene mutations ; Gene Rearrangement ; Genes ; Genes, BRCA1 ; Genes, BRCA2 ; Genetic aspects ; genomics ; Gynecology. Andrology. Obstetrics ; Health aspects ; Humans ; Introns ; Male ; Mammary gland diseases ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; Mutation ; Oncology ; Ovarian cancer ; Ovarian Neoplasms - genetics ; Point Mutation ; Risk ; Risk factors ; Risk groups ; Tumors</subject><ispartof>Breast cancer research and treatment, 2011-04, Vol.126 (3), p.705-716</ispartof><rights>Springer Science+Business Media, LLC. 2010</rights><rights>2015 INIST-CNRS</rights><rights>COPYRIGHT 2011 Springer</rights><rights>Springer Science+Business Media, LLC. 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c574t-c76eb9c2a2c2431537eea4300793376ee533f65acf0ec2a7f9bd3de763bd5cfe3</citedby><cites>FETCH-LOGICAL-c574t-c76eb9c2a2c2431537eea4300793376ee533f65acf0ec2a7f9bd3de763bd5cfe3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10549-010-1170-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10549-010-1170-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23982093$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20859677$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Gonzalez-Hormazabal, Patricio</creatorcontrib><creatorcontrib>Gutierrez-Enriquez, Sara</creatorcontrib><creatorcontrib>Gaete, Daniel</creatorcontrib><creatorcontrib>Reyes, Jose M.</creatorcontrib><creatorcontrib>Peralta, Octavio</creatorcontrib><creatorcontrib>Waugh, Enrique</creatorcontrib><creatorcontrib>Gomez, Fernando</creatorcontrib><creatorcontrib>Margarit, Sonia</creatorcontrib><creatorcontrib>Bravo, Teresa</creatorcontrib><creatorcontrib>Blanco, Rafael</creatorcontrib><creatorcontrib>Diez, Orland</creatorcontrib><creatorcontrib>Jara, Lilian</creatorcontrib><title>Spectrum of BRCA1/2 point mutations and genomic rearrangements in high-risk breast/ovarian cancer Chilean families</title><title>Breast cancer research and treatment</title><addtitle>Breast Cancer Res Treat</addtitle><addtitle>Breast Cancer Res Treat</addtitle><description>The distribution of
BRCA1/2
germline mutations in breast/ovarian cancer (BC/OC) families varies among different populations. In the Chilean population, there are only two reports of mutation analysis of
BRCA1/2
, and these included a low number of BC and/or OC patients. Moreover, the prevalence of
BRCA1/2
genomic rearrangements in Chilean and in other South American populations is unknown. In this article, we present the mutation-detection data corresponding to a set of 326 high-risk families analyzed by conformation-sensitive gel electrophoresis and heteroduplex analysis. To determine the contribution of
BRCA1/2
LGRs in Chilean BC patients, we analyzed 56 high-risk subjects with no pathogenic
BRCA1/2
point mutations. Germline
BRCA1
/
2
point mutations were found in 23 (7.1%) of the 326 Chilean families. Families which had at least three BC and/or OC cases showed the highest frequency of mutations (15.9%). We identified 14 point pathogenic mutations. Three recurrent mutations in
BRCA1
(c.187_188delAG, c.2605_2606delTT, and c.3450_3453delCAAG) and three in
BRCA2
(c.4969_4970insTG, c.5374_5377delTATG, and c.6503_6504delTT) contributed to 63.6 and 66.7% of all the deleterious mutations of each gene, which may reflect the presence of region-specific founder effects. Taken together
BRCA1/2
recurrent point mutations account for 65.2% (15/23) of the
BRCA1/2
(+) families. No large deletions or duplications involving
BRCA1
/
2
were identified in a subgroup of 56 index cases negative for
BRCA1/2
point mutations. Our study, which is the largest conducted to date in a South American population, provides a comprehensive analysis on the type and distribution of
BRCA1/2
mutations and allelic variants.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>BRCA1 protein</subject><subject>BRCA2 protein</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms, Male - genetics</subject><subject>Cancer</subject><subject>Cancer research</subject><subject>Chile</subject><subject>Data processing</subject><subject>Epidemiology</subject><subject>Exons</subject><subject>Family Health</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>Founder Effect</subject><subject>Gel electrophoresis</subject><subject>Gene mutations</subject><subject>Gene Rearrangement</subject><subject>Genes</subject><subject>Genes, BRCA1</subject><subject>Genes, BRCA2</subject><subject>Genetic aspects</subject><subject>genomics</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Introns</subject><subject>Male</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Mutation</subject><subject>Oncology</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms - genetics</subject><subject>Point Mutation</subject><subject>Risk</subject><subject>Risk factors</subject><subject>Risk groups</subject><subject>Tumors</subject><issn>0167-6806</issn><issn>1573-7217</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9ktuO0zAQhiMEYruFB-AGWaAFbrL1IY7jy1JxklZC4nAduc649ZLYxU6Q-vZMaWFZBMgX1mi-mdE_8xfFI0YvGaVqkRmVlS4poyVjipb7O8WMSSVKxZm6W8woq1VZN7Q-K85zvqaUakX1_eKM00bqWqlZkT7uwI5pGkh05OWH1ZItONlFH0YyTKMZfQyZmNCRDYQ4eEsSmJRM2MAAYczEB7L1m22ZfP5C1pjM4yJ-M8mbQKwJFhJZbX0PGDoz-N5DflDcc6bP8PD0z4vPr199Wr0tr96_ebdaXpVWqmosraphrS033PJKMCkUgKkE6tZCYA6kEK6WxjoKSCmn153oQNVi3UnrQMyL58e-uxS_TpDHdvDZQt-bAHHKbYNjGt5ohuSL_5KMMqWbmlca0Sd_oNdxSgF1YL-mUkxSidDTI7QxPbQ-uDgmYw8926WQUgtd8UOry79Q-DrARccADvd2u-DZbwVbMP24zbGffhzpNsiOoE0x5wSu3SU_mLRHJe3BOe3ROS09xOicdo81j0_CpvUA3a-Kn1ZB4OIEmGxN79AE1ucbTuiGUzzNvOBHLmMKfZJuNvTv6d8BAkTZcQ</recordid><startdate>20110401</startdate><enddate>20110401</enddate><creator>Gonzalez-Hormazabal, Patricio</creator><creator>Gutierrez-Enriquez, Sara</creator><creator>Gaete, Daniel</creator><creator>Reyes, Jose M.</creator><creator>Peralta, Octavio</creator><creator>Waugh, Enrique</creator><creator>Gomez, Fernando</creator><creator>Margarit, Sonia</creator><creator>Bravo, Teresa</creator><creator>Blanco, Rafael</creator><creator>Diez, Orland</creator><creator>Jara, Lilian</creator><general>Springer US</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20110401</creationdate><title>Spectrum of BRCA1/2 point mutations and genomic rearrangements in high-risk breast/ovarian cancer Chilean families</title><author>Gonzalez-Hormazabal, Patricio ; Gutierrez-Enriquez, Sara ; Gaete, Daniel ; Reyes, Jose M. ; Peralta, Octavio ; Waugh, Enrique ; Gomez, Fernando ; Margarit, Sonia ; Bravo, Teresa ; Blanco, Rafael ; Diez, Orland ; Jara, Lilian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c574t-c76eb9c2a2c2431537eea4300793376ee533f65acf0ec2a7f9bd3de763bd5cfe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>BRCA1 protein</topic><topic>BRCA2 protein</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms, Male - genetics</topic><topic>Cancer</topic><topic>Cancer research</topic><topic>Chile</topic><topic>Data processing</topic><topic>Epidemiology</topic><topic>Exons</topic><topic>Family Health</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>Founder Effect</topic><topic>Gel electrophoresis</topic><topic>Gene mutations</topic><topic>Gene Rearrangement</topic><topic>Genes</topic><topic>Genes, BRCA1</topic><topic>Genes, BRCA2</topic><topic>Genetic aspects</topic><topic>genomics</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Introns</topic><topic>Male</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Mutation</topic><topic>Oncology</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms - genetics</topic><topic>Point Mutation</topic><topic>Risk</topic><topic>Risk factors</topic><topic>Risk groups</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gonzalez-Hormazabal, Patricio</creatorcontrib><creatorcontrib>Gutierrez-Enriquez, Sara</creatorcontrib><creatorcontrib>Gaete, Daniel</creatorcontrib><creatorcontrib>Reyes, Jose M.</creatorcontrib><creatorcontrib>Peralta, Octavio</creatorcontrib><creatorcontrib>Waugh, Enrique</creatorcontrib><creatorcontrib>Gomez, Fernando</creatorcontrib><creatorcontrib>Margarit, Sonia</creatorcontrib><creatorcontrib>Bravo, Teresa</creatorcontrib><creatorcontrib>Blanco, Rafael</creatorcontrib><creatorcontrib>Diez, Orland</creatorcontrib><creatorcontrib>Jara, Lilian</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Breast cancer research and treatment</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gonzalez-Hormazabal, Patricio</au><au>Gutierrez-Enriquez, Sara</au><au>Gaete, Daniel</au><au>Reyes, Jose M.</au><au>Peralta, Octavio</au><au>Waugh, Enrique</au><au>Gomez, Fernando</au><au>Margarit, Sonia</au><au>Bravo, Teresa</au><au>Blanco, Rafael</au><au>Diez, Orland</au><au>Jara, Lilian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Spectrum of BRCA1/2 point mutations and genomic rearrangements in high-risk breast/ovarian cancer Chilean families</atitle><jtitle>Breast cancer research and treatment</jtitle><stitle>Breast Cancer Res Treat</stitle><addtitle>Breast Cancer Res Treat</addtitle><date>2011-04-01</date><risdate>2011</risdate><volume>126</volume><issue>3</issue><spage>705</spage><epage>716</epage><pages>705-716</pages><issn>0167-6806</issn><eissn>1573-7217</eissn><coden>BCTRD6</coden><abstract>The distribution of
BRCA1/2
germline mutations in breast/ovarian cancer (BC/OC) families varies among different populations. In the Chilean population, there are only two reports of mutation analysis of
BRCA1/2
, and these included a low number of BC and/or OC patients. Moreover, the prevalence of
BRCA1/2
genomic rearrangements in Chilean and in other South American populations is unknown. In this article, we present the mutation-detection data corresponding to a set of 326 high-risk families analyzed by conformation-sensitive gel electrophoresis and heteroduplex analysis. To determine the contribution of
BRCA1/2
LGRs in Chilean BC patients, we analyzed 56 high-risk subjects with no pathogenic
BRCA1/2
point mutations. Germline
BRCA1
/
2
point mutations were found in 23 (7.1%) of the 326 Chilean families. Families which had at least three BC and/or OC cases showed the highest frequency of mutations (15.9%). We identified 14 point pathogenic mutations. Three recurrent mutations in
BRCA1
(c.187_188delAG, c.2605_2606delTT, and c.3450_3453delCAAG) and three in
BRCA2
(c.4969_4970insTG, c.5374_5377delTATG, and c.6503_6504delTT) contributed to 63.6 and 66.7% of all the deleterious mutations of each gene, which may reflect the presence of region-specific founder effects. Taken together
BRCA1/2
recurrent point mutations account for 65.2% (15/23) of the
BRCA1/2
(+) families. No large deletions or duplications involving
BRCA1
/
2
were identified in a subgroup of 56 index cases negative for
BRCA1/2
point mutations. Our study, which is the largest conducted to date in a South American population, provides a comprehensive analysis on the type and distribution of
BRCA1/2
mutations and allelic variants.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>20859677</pmid><doi>10.1007/s10549-010-1170-y</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0167-6806 |
ispartof | Breast cancer research and treatment, 2011-04, Vol.126 (3), p.705-716 |
issn | 0167-6806 1573-7217 |
language | eng |
recordid | cdi_proquest_miscellaneous_857482891 |
source | MEDLINE; SpringerLink Journals - AutoHoldings |
subjects | Adult Biological and medical sciences BRCA1 protein BRCA2 protein Breast cancer Breast Neoplasms - genetics Breast Neoplasms, Male - genetics Cancer Cancer research Chile Data processing Epidemiology Exons Family Health Female Female genital diseases Founder Effect Gel electrophoresis Gene mutations Gene Rearrangement Genes Genes, BRCA1 Genes, BRCA2 Genetic aspects genomics Gynecology. Andrology. Obstetrics Health aspects Humans Introns Male Mammary gland diseases Medical sciences Medicine Medicine & Public Health Middle Aged Mutation Oncology Ovarian cancer Ovarian Neoplasms - genetics Point Mutation Risk Risk factors Risk groups Tumors |
title | Spectrum of BRCA1/2 point mutations and genomic rearrangements in high-risk breast/ovarian cancer Chilean families |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T20%3A07%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Spectrum%20of%20BRCA1/2%20point%20mutations%20and%20genomic%20rearrangements%20in%20high-risk%20breast/ovarian%20cancer%20Chilean%20families&rft.jtitle=Breast%20cancer%20research%20and%20treatment&rft.au=Gonzalez-Hormazabal,%20Patricio&rft.date=2011-04-01&rft.volume=126&rft.issue=3&rft.spage=705&rft.epage=716&rft.pages=705-716&rft.issn=0167-6806&rft.eissn=1573-7217&rft.coden=BCTRD6&rft_id=info:doi/10.1007/s10549-010-1170-y&rft_dat=%3Cgale_proqu%3EA355939429%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=858471505&rft_id=info:pmid/20859677&rft_galeid=A355939429&rfr_iscdi=true |